See more : Doseology Sciences Inc. (DOSEF) Income Statement Analysis – Financial Results
Complete financial analysis of Finch Therapeutics Group, Inc. (FNCH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Finch Therapeutics Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- LMP Automotive Holdings, Inc. (LMPX) Income Statement Analysis – Financial Results
- Asia Financial Holdings Limited (AIFIF) Income Statement Analysis – Financial Results
- Dubber Corporation Limited (DUBRF) Income Statement Analysis – Financial Results
- Softstar Entertainment Inc. (6111.TWO) Income Statement Analysis – Financial Results
- M3 Technology Inc. (6799.TW) Income Statement Analysis – Financial Results
Finch Therapeutics Group, Inc. (FNCH)
About Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 107.00K | 861.00K | 18.53M | 7.72M | 10.15M |
| Cost of Revenue | 7.20M | 5.51M | 57.28M | 33.14M | 314.00K |
| Gross Profit | -7.09M | -4.65M | -38.75M | -25.43M | 9.84M |
| Gross Profit Ratio | -6,628.04% | -539.61% | -209.08% | -329.38% | 96.91% |
| Research & Development | 7.20M | 57.89M | 57.28M | 33.14M | 23.54M |
| General & Administrative | 26.91M | 38.09M | 21.24M | 14.01M | 7.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.91M | 38.09M | 21.24M | 14.01M | 7.44M |
| Other Expenses | 0.00 | 947.00K | 1.83M | 2.00K | 40.00K |
| Operating Expenses | 32.59M | 95.98M | 78.52M | 47.16M | 30.98M |
| Cost & Expenses | 34.11M | 95.98M | 78.52M | 47.16M | 31.30M |
| Interest Income | 1.57M | 252.00K | 22.00K | 106.00K | 488.00K |
| Interest Expense | 0.00 | 35.44M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.52M | 5.51M | 2.30M | 790.00K | 482.00K |
| EBITDA | -32.48M | -82.69M | -57.68M | -38.65M | -20.66M |
| EBITDA Ratio | -30,357.01% | -8,669.80% | -323.68% | -500.49% | -202.09% |
| Operating Income | -34.00M | -115.59M | -59.99M | -39.44M | -21.14M |
| Operating Income Ratio | -31,777.57% | -13,425.44% | -323.68% | -510.90% | -208.21% |
| Total Other Income/Expenses | -44.21M | 947.00K | 1.83M | 95.00K | 388.00K |
| Income Before Tax | -78.22M | -114.65M | -58.16M | -39.34M | -20.75M |
| Income Before Tax Ratio | -73,098.13% | -13,315.45% | -313.84% | -509.66% | -204.39% |
| Income Tax Expense | -3.46M | -947.00K | -2.30M | -93.00K | -348.00K |
| Net Income | -74.75M | -113.70M | -55.86M | -39.25M | -20.41M |
| Net Income Ratio | -69,863.55% | -13,205.46% | -301.42% | -508.46% | -200.97% |
| EPS | -46.59 | -71.52 | -35.27 | -24.39 | -12.68 |
| EPS Diluted | -46.59 | -71.52 | -35.27 | -24.39 | -12.68 |
| Weighted Avg Shares Out | 1.60M | 1.59M | 1.58M | 1.61M | 1.61M |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.59M | 1.58M | 1.61M | 1.61M |
Finch Therapeutics Appoints Samuel Allen Hamood to its Board of Directors
Finch Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Finch Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program
Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes
Finch Therapeutics: Gut Instinct Says Buy
Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
Finch Therapeutics Announces Pricing of Upsized Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports